HighPoint Advisor Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.4M | Sell |
52,428
-198,802
| -79% | -$44.1M | 0.48% | 50 |
|
|
2025
Q4 | $57.4M | Buy |
251,230
+68,333
| +37% | +$15.6M | 1.26% | 13 |
|
|
2025
Q3 | $42.3M | Buy |
182,897
+2,527
| +1% | +$515K | 2.02% | 6 |
|
|
2025
Q2 | $33.5M | Buy |
180,370
+5,604
| +3% | +$1.04M | 1.78% | 7 |
|
|
2025
Q1 | $33.8M | Buy |
174,766
+833
| +0.5% | +$162K | 1.97% | 6 |
|
|
2024
Q4 | $33.3M | Sell |
173,933
-1,193
| -0.7% | -$219K | 1.81% | 7 |
|
|
2024
Q3 | $34.6M | Sell |
175,126
-3,287
| -2% | -$613K | 2.02% | 6 |
|
|
2024
Q2 | $33.3M | Buy |
178,413
+2,050
| +1% | +$340K | 1.99% | 6 |
|
|
2024
Q1 | $28.4M | Buy |
176,363
+262
| +0.1% | +$45.2K | 2.01% | 6 |
|
|
2023
Q4 | $31.4M | Buy |
+176,101
| New | +$25.7M | 2.25% | 6 |
|
|
2022
Q2 | $25.1M | Buy |
+164,743
| New | +$25.2M | 2.75% | 5 |
|
|
2021
Q3 | $18.8M | Buy |
174,109
+2,840
| +2% | +$325K | 1.84% | 8 |
|
|
2021
Q2 | $19.3M | Buy |
171,269
+722
| +0.4% | +$81.3K | 1.94% | 6 |
|
|
2021
Q1 | $18.3M | Sell |
170,547
-24,362
| -12% | -$2.61M | 2.12% | 6 |
|
|
2020
Q4 | $20.5M | Buy |
194,909
+86,948
| +81% | +$8.36M | 2.5% | 5 |
|
|
2020
Q3 | $10.1M | Buy |
107,961
+10,872
| +11% | +$1.02M | 1.83% | 7 |
|
|
2020
Q2 | $9.63M | Buy |
97,089
+4,456
| +5% | +$392K | 2.06% | 6 |
|
|
2020
Q1 | $7.74M | Buy |
92,633
+2,806
| +3% | +$239K | 1.84% | 10 |
|
|
2019
Q4 | $7.89M | Buy |
89,827
+10,545
| +13% | +$875K | 1.63% | 12 |
|
|
2019
Q3 | $6.75M | Buy |
79,282
+7,325
| +10% | +$502K | 1.49% | 12 |
|
|
2019
Q2 | $4.89M | Sell |
71,957
-649
| -0.9% | -$51K | 1.15% | 18 |
|
|
2019
Q1 | $5.66M | Buy |
72,606
+6,011
| +9% | +$492K | 1.39% | 15 |
|
|
2018
Q4 | $5.36M | Buy |
66,595
+1,359
| +2% | +$120K | 1.42% | 15 |
|
|
2018
Q3 | $5.5M | Sell |
65,236
-1,289
| -2% | -$122K | 1.51% | 11 |
|
|
2018
Q2 | $6.53M | Sell |
66,525
-1,259
| -2% | -$123K | 1.76% | 9 |
|
|
2018
Q1 | $6.81M | Buy |
67,784
+21,140
| +45% | +$2.32M | 1.87% | 8 |
|
|
2017
Q4 | $5.22M | Sell |
46,644
-929
| -2% | -$87.6K | 1.49% | 13 |
|
|
2017
Q3 | $4.33M | Sell |
47,573
-13,126
| -22% | -$999K | 1.34% | 13 |
|
|
2017
Q2 | $4.31M | Hold |
60,699
| – | – | 1.39% | 15 |
|
|
2017
Q1 | $4.31M | Buy |
60,699
+4,425
| +8% | +$278K | 1.39% | 15 |
|
|
2016
Q4 | $3.54M | Buy |
56,274
+657
| +1% | +$40.1K | 1.14% | 17 |
|
|
2016
Q3 | $3.43M | Buy |
55,617
+35,402
| +175% | +$2.29M | 1.21% | 15 |
|
|
2016
Q2 | $1.24M | Hold |
20,215
| – | – | 0.44% | 56 |
|
|
2016
Q1 | $1.24M | Buy |
20,215
+2,571
| +15% | +$143K | 0.76% | 32 |
|
|
2015
Q4 | $1.04M | Buy |
17,644
+28
| +0.2% | +$1.61K | 0.68% | 35 |
|
|
2015
Q3 | $958K | Buy |
+17,616
| New | +$1.15M | 1.06% | 24 |
|
Other funds holding ABBV
VCM
VPM
HighPoint Advisor Group's ABBV Position: Q1 2026 in Review
HighPoint Advisor Group reduced its AbbVie (ABBV) stake by 79% in Q1 2026, selling an estimated $44.1M and leaving 52,428 shares worth $11.4M. The position accounts for 0.48% of the portfolio, ranked #50.
HighPoint Advisor Group first reported a position in ABBV in Q3 2015 and has held it in 36 quarters since. The position peaked at $57.4M in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- HighPoint Advisor Group held 52,428 shares of AbbVie worth $11.4M as of Q1 2026.
- HighPoint Advisor Group sold 198,802 AbbVie shares in Q1 2026, an estimated $44.1M.
- AbbVie made up 0.48% of HighPoint Advisor Group's portfolio in Q1 2026, its #50 holding.
- HighPoint Advisor Group first reported a position in AbbVie in Q3 2015 and has held it in 36 quarters since.
- HighPoint Advisor Group's AbbVie position peaked at $57.4M in Q4 2025.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on HighPoint Advisor Group's 13F filing for Q1 2026, filed 14 May 2026.